Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brigatinib after alectinib or ceritinib in ALK+ NSCLC (China)
CTR20182341Phase 2Completed
- Sponsor
- ARIAD Pharmaceuticals, Inc.
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brigatinib in ALK-positive non-small cell lung cancer, sponsored by ARIAD Pharmaceuticals, Inc.. Started Mar 2019; status: completed.
02
Drugs
brigatinib
03
Conditions
ALK-positive non-small cell lung cancer
Beyond the preview
Go deeper on CTR20182341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20182341.